HILIC-LC-MS/MS quantitative method for the cellular analysis of varying structures of gemini surfactants designed as nanomaterial drug carriers by Donkuru, McDonald et al.
Cite this article as : Donkuru, M., Michel, D., Awad, H. et al.  J Chromatogr A. 2016 1446: 114-24. Final 
publication is available via http://dx.doi.org/10.1016/j.chroma.2016.04.013. 
 
1 
University of Saskatchewan Author Manuscript, available May 13, 2018.  
 
Published title 
Hydrophilic interaction liquid chromatography–tandem mass 
spectrometry quantitative method for the cellular analysis of varying 
structures of gemini surfactants designed as nanomaterial drug carriers 
 
Alternate title  
HILIC-LC-MS/MS quantitative method for the cellular analysis of 
varying structures of gemini surfactants designed as nanomaterial drug 
carriers. 
 
McDonald Donkuru1, Deborah Michel1, Hanan Awad1, George Katselis2, Anas El-Aneed1 
 
1. Drug Design & Discovery Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 
Wiggins Road, Saskatoon, SK  S7N 5E5, Canada 
2. Canadian Centre for Health and Safety in Agriculture (CCHSA), and Department of Medicine, University 
of Saskatchewan, 104 Clinic Place, Saskatoon, SK  S7N 2Z4, Canada 
 
SHORT TITLE:  HILIC-LC-MS/MS METHOD FOR THE BIO-ANALYSIS OF GEMINI SURFACTANT
ABSTRACT 
Diquaternary gemini surfactants have successfully been used to form lipid-based nanoparticles 
that are able to compact, protect, and deliver genetic materials into cells. However, what happens 
to the gemini surfactants after they have released their therapeutic cargo is unknown. Such 
knowledge is critical to assess the quality, safety, and efficacy of gemini surfactant nanoparticles. 
We have developed a simple and rapid liquid chromatography electrospray ionization-tandem 
mass spectrometry (LC-ESI–MS/MS) method for the quantitative determination of various 
structures of gemini surfactants in cells. Hydrophilic interaction liquid chromatography (HILIC) 
was employed allowing for a short simple isocratic run of only 4 minutes. The lower limit of 
detection (LLOD) was 3 ng/mL. The method was valid to 18 structures of gemini surfactants 
belonging to two different structural families. A full method validation was performed for two 
lead compounds according to USFDA guidelines. The HILIC-MS/MS was compatible with the 
physicochemical properties of gemini surfactants that bear a permanent positive charge with both 
hydrophilic and hydrophobic elements within their molecular structure. In addition, an effective 
liquid-liquid extraction method (98% recovery) was employed surpassing previously used 
extraction methods. The analysis of nanoparticle-treated cells showed an initial rise in the analyte 
intracellular concentration followed by a maximum and a somewhat more gradual decrease of 
the intracellular concentration. The observed intracellular depletion of the gemini surfactants 
may be attributable to the bio-transformation into metabolites and exocytosis from the host cells. 
Obtained cellular data showed a pattern that grants additional investigations , evaluating 
metabolite formation and assessing the subcellular distribution of tested compounds.   
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ABBREVIATIONS 
16-3-16:   N,N-bis(dimethylhexadecyl)-1,3-propane-diammonium  
16-3-16-d66:   N,N-bis(dimethylhexadecyl-d16)-1,3-propane-diammonium  
16(Py)-S-2-S-(Py)16:  1,1'-[ethane-1,2-diylbis(sulfanediylhexadecane-1,2-
diyl)]dipyridinium 
16(Py)-S-2-S-(Py)16-d10: 1,1'-[ethane-1,2-diylbis(sulfanediylhexadecane-1,2-
diyl)]dipyridinium-d10 
CID:    Collision-induced dissociation 
DOPE:    1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine   
DESI:    Desorption electrospray ionization   
DNA:    Deoxyribonucleic acid 
ESI:    Electrospray ionization 
FBS:    Fetal bovine serum 
FC:    Fast chromatography 
GS1:    Nebulizer gas   
GS2:    Heater gas 
HILIC:   Hydrophilic interaction liquid chromatography 
HQC:    High quality control 
LC-ESI-MS/MS:   Liquid chromatography-Electrospray Ionization- tandem mass 
spectrometry 
LLE:    Liquid-liquid extraction 
LLOD:   Lower limit of detection 
LLOQ:   Lower limit of quantification 
LQC:    Low quality control 
MALDI:   Matrix assisted laser desorption 
MEM:    Minimum essential media (Eagleꞌs formulation) 
MRM:    Multiple reaction monitoring 
MQC:    Medium quality control 
PBS:    Phosphate-buffered saline 
P/G/L:   Plasmid, gemini surfactant and lipid as components 
pGT·IFN-GFP:  DNA in plasmid form, coding for IFN-γ protein 
RSD:    Relative standard deviation 
Rt:    Retention time 
S/N:    Signal-to-noise ratio 
TEA:    Triethyl amine 
USFDA:   United States Food and Drugs Administration 
v/v:    Volume-to-volume ratio 
ZIC:    Zwitterionic 
 
1. INTRODUCTION 
Dicationic gemini surfactants are a promising class of lipids for nanoparticle-mediated 
gene delivery [1,2,3] as they bind to DNA and facilitate its entry into cells. However, the fate of 
gemini surfactants after they have released their therapeutic cargo is unknown. Effective 
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analytical methods are needed to assess the quality, safety, and efficacy of gemini surfactant 
nanoparticles.   
Gemini surfactants consist of two monomer surfactants with polar or ionic head-groups 
connected via a spacer moiety (Figure 1A). In dicationic gemini surfactants (frequently used as 
the bromide salts), the head-groups are positively charged to allow DNA complexation. The 
structural modification in gemini surfactants increases transfection efficiency and reduces 
toxicity. In fact, a variety of gemini surfactant structures demonstrate effectiveness as non-viral 
DNA delivery agents.[4,5,6,7]  
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) offers the 
combined capability of analyte separation alongside sensitive, high-throughput, and selective 
analysis.[8,9,10] Gemini surfactants are not compatible with fluorescent/UV-detection due to the 
lack of fluorescent or UV-active moieties. Therefore, LC-MS/MS is an ideal platform for the 
quantitative determination of the nanoparticles' amphiphilic constituents within complex 
biological mixtures. In addition, LC-MS/MS analysis using multiple reaction monitoring (MRM) 
allows gemini surfactants to be monitored using precursor ion-to-production diagnostic 
transitions, which provides specificity to target gemini surfactant analytes.  
To allow for the assessment of the cellular fate of gemini surfactants, our laboratory 
initiated studies to establish the collision-induced dissociation (CID)-MS/MS fragmentation 
patterns of several gemini surfactant structures.[11,12,13,14] These qualitative studies allowed 
for the subsequent development of an LC- (electrospray ionization) ESI-MS/MS method 
employing a cyano chromatographic column for the quantification of gemini surfactants in 
epidermal keratinocytes.[15] However, this method suffered from drawbacks, such as ion 
suppression due to the addition of an ion pairing reagent, long run times, and the use of gradient 
elution. Other MS-based quantification methods, such as fast chromatography (FC)-MS, 
desorption electrospray ionization (DESI-MS/MS), and matrix-assisted laser desorption 
(MALDI)-MS were also developed in our lab and their analytical capabilities were 
compared;[16] however, all the developed methods were only applicable to one structural family 
of gemini surfactants with full validation possible for the N,N-bis(dimethylhexadecyl)-1,3-
propanediammonium compound, denoted as 16-3-16 (Figure 1B). In fact, the fastest MS 
quantification method,[16] MALDI-MS, was not applicable to gemini surfactant structures that 
have more than three carbons within their spacer region due to the incomplete dissociation of the 
gemini surfactants within the MALDI source; preventing the possibility of developing 
quantification methods. Hence, there is need for a universal method that can produce quantitative 
data for varying gemini surfactant structures through the adoption of suitable chromatographic 
platform such as hydrophilic interaction liquid chromatography (HILIC). HILIC is an ideal 
stationary phase that can combine the benefits of both the normal and reversed-phase of 
separation.[17] It has been widely used for the analysis of polar compounds including those 
bearing quaternary amines.[18] 
In addition to traditional, non-substituted alkanediyl-α,ω-bis(dimethyl alkyl-ammonium) 
gemini surfactants (designated as m-s-m), other classes of gemini surfactants, especially 
bis(alkyl-pyridinum) compounds, have emerged.[19,20] The latter are reported to be less toxic 
when compared to m-s-m.[19] The representative m-s-m compound is N,N-
bis(dimethylhexadecyl)-1,3-propanediammonium (denoted 16-3-16; Figure 1B), while its 
bis(alkyl-pyridinum) counterpart is 1,1'-[ethane-1,2-diylbis(sulfanediylhexadecane-1,2-
Cite this article as : Donkuru, M., Michel, D., Awad, H. et al.  J Chromatogr A. 2016 1446: 114-24. Final 
publication is available via http://dx.doi.org/10.1016/j.chroma.2016.04.013. 
 
4 
University of Saskatchewan Author Manuscript, available May 13, 2018.  
diyl)]dipyridinium (denoted 16(Py)-S-2-S-(Py)16; Figure 1C). The 16-3-16 compound imposed 
higher toxicity than 16(Py)-S-2-S-(Py)16 [19,21] irrespective of its molecular structure. It is 
hypothesized that possible differences in how gemini surfactants enter the cells, or in bio 
interactions, bio-distribution, bio-transformation, or bio-persistence, could explain differences in 
toxicity. Therefore, we developed a simple and fast LC-ESI-MS/MS method that can effectively 
quantify varying structures of gemini surfactants within treated cells. 
Herein, we report the utilization of HILIC-LC-MS/MS to allow for the quantitative 
determination of variable structures of gemini surfactants within cells. The method is fast (4 
min), simple, and requires an isocratic mobile phase. As we discuss below, its analytical 
capability surpasses previously developed methods. In fact, for the first time, we were able to 
quantify gemini surfactants that belong to two different structural families, namely 16-3-16 and 
16(Py)-S-2-S-(Py)16 (Figure 1). 
 
2. MATERIALS AND METHODS 
2.1 Materials 
Diquaternary ammonium and dipyridinium gemini surfactants and their deuterated internal 
standards were synthesized based on established methods.[19,22,23] For the 16-13-6 analyte, the 
internal standard (16-13-6-d66) incorporated deuterated alkyl tails, resulting in a mass difference 
of +66 Da; while for 16(Py)-S-2-S-(Py)16, deuteration was within the pyridinium heads, 
accounting for a +10 Da mass difference with the internal standard, 16(Py)-S-2-S-(Py)16-d10 
(Figure S1 in the supplementary information). 
The neutral lipid 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was purchased 
from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Chloroform, methanol, and 1-Octanol 
(99%) were purchased from Fisher Scientific (Ottawa, ON, Canada). Ammonium formate, 
formic acid, mass spectrometric-grade water, and acetonitrile were purchased from Fisher 
Scientific (Ottawa, ON, Canada). PAM 212 cells were kindly provided by Dr. S. Yuspa, National 
Cancer Institute, Bethesda, MD, USA. The cell growth medium contained minimum essential 
media (MEM), fetal bovine serum albumin (FBS), and antibiotic-antimycotic obtained from 
Sigma-Aldrich (Oakville, ON, Canada). Tissue culture flasks (with capacities: 150-cm3, 75-cm3, 
25-cm3) as well as 6-well plates, were purchased from Fisher Scientific (Ottawa, ON, Canada). 
2.2 LC-MS/MS instrumentation 
The hybrid LC-ESI-MS/MS analytical system comprised an Agilent 1200 Series HPLC 
with a quaternary pump, degasser, and auto sampler (Agilent Technologies, Mississauga, ON, 
Canada) coupled to an AB Sciex API 4000 QTRAP mass spectrometer (AB Sciex, Concord, ON, 
Canada). The chromatography step used a ZIC®-HILIC column (150 × 2.1 mm, 5 µm, 200 Å; 
Merck SeQuant AB) held at 50 ˚C and an isocratic mobile phase flowing at500 µL/min to 
analyze 2 µL injected aliquots. The mobile phase was 80:20 (v/v) acetonitrile/buffer, with the 
buffer containing 2.5 mM ammonium formate and 25 mM formic acid. No sample carryover was 
detected and to eliminate any chances of carryover, double blank injections were run after the 
injection of the highest calibration curve concentration. 
The AB Sciex QTRAP 4000 mass spectrometer is equipped with an ESI source set at 5500 
V ionspray voltage and 600 ºC at the ion source interface, with 30 psi being set as the curtain gas 
pressure and 40 psi as the pressures for both GS1 (nebulizer gas) and GS2 (heater gas). The mass 
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spectrometry data were obtained using low energy collision tandem mass spectrometry CID-
MS/MS operated in the multiple reaction monitoring (MRM) mode to monitor the analytes and 
the deuterated internal standards as [M]2+ species, including the following transitions: 16-3-16 
[M]2+ m/z 290.33 → 355.40, 86.11; 16-3-16-d66 [M]2+ m/z 323.54 → 388.61; and, 16(Py)-S-2-S-
(Py)16 [M]2+ m/z 349.28 → 396.28, 203.09; 16(Py)-S-2-S-(Py)16-d10 [M]2+ m/z 354.31 → 
401.31. The MRM conditions and fingerprint structures for the monitored transitions are 
presented below (Table 1, Figure 1, and Figure S1 in the supplementary information). 
2.3 Preparation of standard solutions 
Aqueous stock solutions of all gemini surfactants (3 mM) were used with or without 
dilutions and stored at -20 ˚C under darkness. The mass concentrations (equivalent to 3 mM) for 
analytical quantitation are detailed on Table S1. An isotonic sucrose solution (9.25% w/v, pH 9) 
containing DOPE vesicles (1 mM) was prepared fresh. Plasmid DNA (pGT·IFN-GFP) solution, 
40 µg/mL, was prepared in ultrapure, organic-free water and stored at -20 ˚C. The DOPE and 
plasmid DNA solutions were used without further dilutions. 
2.4 Preparation of nanoparticle formulations 
Plasmid DNA/gemini surfactant/lipid DOPE (P/G/L) nano-lipoplex formulations were 
prepared in a 1:10:100 molar ratio (combined in the order given) as previously described.[22] 
The mole of DNA is calculated per DNA base-pair with an average molecular weight of 660 
Da.[24] Briefly, the required transfection dose of plasmid DNA was measured, to which the 
appropriate amount of gemini surfactant was added with an allowed 30-minute incubation at 
room temperature. DOPE was then added to the binary mixture, followed by a further 15-minute 
incubation at room temperature to obtain a ternary (final) P/G/L system. The transfection dose 
of plasmid DNA was 0.3 µg for 1 × 106 cells/treatment. 
2.5 PAM 212 cell treatment and sample collection 
PAM 212 cells were routinely cultured inside humidified 95% air/5% CO2 incubators at 37 
˚C. The MEM culture medium was supplemented with 10% FBS and 1 unit/mL antibiotic-
antimycotic. Cells cultured to 80% confluence were harvested by trypsinization and either 
subcultured or prepared for treatment. At 24 h before treatment, cells were seeded at 1 × 106 
cells/mL/well within 6-well plate format. At 1 h to transfection, the cell supernatant media was 
replaced with FBS-free media. Nanoparticle formulations, freshly prepared (Section 2.3), were 
added and allowed to interact with cells by placing them in the CO2 incubator (37 ˚C). This 
marked the reference point for recording any post-treatment incubation time-points when further 
steps are taken. 
After 5 hours, the nanoparticle-dosed cell media was replaced with supplemented media 
(MEM with 10% FBS, 1 unit/mL), followed by a continued incubation of cells. All treatments 
were carried out in replicates (n ≥ 3) along with appropriate controls on at least three separate 
days. The controls included cells that underwent no treatment as well as cells that received 
formulation prepared without the inclusion of the gemini surfactant component. During the 
incubation period, replicates of treated cell samples were, at different time-points, trypsinized 
and collected into 1.5 mL volumes. The collected cells were pelleted (14,000 rpm, 5 min, 4 ˚C), 
rinsed with phosphate-buffered saline (PBS), reconstituted into smaller sample volumes of 200 
µL in PBS, and stored at -80 ˚C prior to analyte extraction and LC-ESI-MS/MS analysis. 
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To better conduct sample collection and reduce tediousness in the process, an alternative 
approach was also used. During the post-treatment incubation period, replicates of treated cells 
were, at different time-points, retrieved from the CO2 incubator, rinsed (3×) with PBS and placed 
at -80 ˚C. All cells kept at -80 ˚C were then thawed, trypsinized, and collected into 1.5-mL 
volumes. The 1.5-mL samples were reduced into smaller sample volumes of 200 µL using 
centrifugal evaporation (speed vacuum concentration). Results were identical using both 
approaches.  
2.6 Sample Preparation for LC-ESI-MS/MS analysis 
The 200-µL treated cell samples kept at -80 ˚C were lysed by six freeze/thaw cycles along 
with 1-h sonication at 25 kHz. The samples were spiked with constant amounts of the internal 
standards by addition of 50-µL solutions obtained from a dilution of 1 250�  parts of the pure stock 
internal standard in water; the resultant concentration was 1,938 ng/mL for 16-3-16-d66 and 
2,086 ng/mL for 16(Py)-2-S-2-(Py)16-d10. For the construction of calibration curves, 200 µL cell 
lysates (equivalent to 1 × 106 cells each), which had not received any nanoparticle treatment, 
were used. The untreated samples were spiked with 50-µL solutions containing the analyte and 
the corresponding internal standard. The resultant volume was 250 µL for all samples prior to 
subsequent steps. 
Liquid-liquid extraction (LLE) of the analytes and internal standards from the cellular 
matrix were achieved using the Bligh/Dyer method.[25] Briefly, the 250-µL samples were 
mixed with 950 µL (3.8 vols) of 2:1 (v/v) methanol/chloroform, followed by mixing with 310 
µL (1.24 vols) of both chloroform and water, in that order. Mixing was achieved by vortexing in 
all cases. The combined mixtures were centrifuged at 14,000 rpm for 10 min at room 
temperature to obtain separate aqueous and organic phases. The bottom organic phase (80% 
portion) was retrieved and dried using a gentle N2 gas stream, followed by reconstitution of the 
extracted analytes in 200 µL of n-octanol prior to LC-ESI-MS/MS analysis. 
For comparison, a recently reported alternative method, octanol extraction, was also 
used.[15] For the octanol extraction, which involves extracting samples with equal volumes of n-
octanol, the 250-µL samples were mixed with 250 µL of n-octanol. Separation of the aqueous 
and organic phases was achieved by centrifugation as above. The organic phase (200-µL, i.e., 
80% portion) was retrieved for LC-ESI-MS/MS analysis. 
2.7 LC-ESI-MS/MS method validation  
The LC-ESI-MS/MS method was validated for the 16-3-16 and 16(Py)-2-S-2-(Py) gemini 
surfactants in accordance with USFDA guidelines.[26,27] Linearity was probed over a wide 
range of analyte concentrations, including 50 – 5,000 ng/mL. Using least-square analysis along 
with 1/χ as the weighting factor, data was processed by plotting the ratio of summed peak areas 
for 16-3-16 and 16(Py)-2-S-2-(Py)16 over the peak areas for their respective internal standards, 
16-3-16-d66 and 16(Py)-2-S-2-(Py)16-d10. Linearity was established with the slope, intercept, and 
coefficient of determination (r2). The limit of detection (LLOD) was set as the lowest detectable 
concentration with a signal-to-noise (S/N) ratio of 3, while the lowest limit of quantification 
(LLOQ) was set at the lowest concentration having S/N ≥ 5, with precision and accuracy within 
±20% of the nominal value as per the USFDA guidelines.[27] 
The intra- and inter-day precision and accuracy of the method was established through the 
analysis of six sample replicates at four different concentrations (lower limit of quantification, 
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LLOQ; lower quality control, LQC; middle quality control, MQC; and high quality control, 
HQC) on three different days. Single assay runs were accepted only when the relative standard 
deviation (RSD) was found to be less than ±15% at concentrations other than the LLOQ, which 
is allowed at ±20%. The criterion for accuracy was set at ±15% of the nominal concentration of 
the QC samples and ±20% for LLOQ.  
Studies involving freeze/thaw stability, bench-top stability, and long-term stability were 
undertaken at LQC, MQC, and HQC. Freeze/thaw stability was tested after three freeze/thaw 
cycles spaced at least 24 h apart with sample storage at -20 ± 5 ˚C between sample thawing. The 
twenty-four hour stability of 16-3-16 and 16(Py)-2-S-2-(Py)16 in PAM212 cell lysate under 
bench-top conditions was evaluated. Predicted concentrations were calculated using newly 
prepared calibration curves. Samples were stored at -20 ± 5 ˚C for 105 days prior to analysis of 
long-term stability. Samples were considered stable when the USFDA criteria for precision and 
accuracy were met.[27]  
 
3. RESULTS - 
3.1 HILIC-LC-MS/MS specificity for gemini surfactant bio-analysis 
The HILIC-LC-MS/MS method provided selectivity through the observed analyte-specific 
retention times and specificity through the MRM mode, which monitors the analytes using 
precursor → product ion transitions. The specific retention times established for each analyte and 
the elimination of carryover effects made the HILIC chromatographic separation an ideal choice 
for the analysis of gemini surfactants. In addition, the HILIC-LC-MS/MS method was applicable 
to various gemini surfactant structures as shown in Table 2. 
A characteristic chemical structure-dependent elution order was observed, establishing 
predictable HILIC retention time trends important for distinguishing the gemini surfactants. For 
instance, the alkyl tail length of three gemini surfactants with the same spacer moiety, increased 
in the order 12(Py)-S-2-S-(Py)12 (tail: dodecyl), 14(Py)-S-2-S-(Py)14 (tail: tetradecyl) and 
16(Py)-S-2-S-(Py)16 (tail: hexadecyl); the corresponding retention times (Rt) decreased in the 
reverse order, 2.88 min, 2.80 min, and 2.62 min, respectively (Table 2). Such a trend was also 
notable in the case of the alkyl spacer portions. The increase in the alkyl spacer chains led to 
shorter retention times as observed for gemini surfactants: 12-3-12 (spacer: propyl) Rt = 2.96, 
12-8-12 (spacer: octyl) Rt = 2.56, 12-12-12 (spacer: dodecyl) Rt = 2.43 min (Table 2). Thus, 
gemini surfactants with longer hydrophobic alkyl tails or longer alkyl spacer chains showed 
shorter retention times on the HILIC column.  
All tested compounds eluted before 4 minutes making the analysis a very fast approach for 
varying gemini surfactant structures. The only exception is 12-7NH-12 eluting at 7.12 min 
(Table 2); this compound contains a secondary amine within the spacer region. Therefore, it 
bears increased polarity within its structure leading to an overall stronger interaction and 
retention on the zwitterionic sulfoalkylbetaine stationary phase (ZIC®-HILIC column).  
In addition, the HILIC-LC-MS/MS platform demonstrated a capability for allowing the 
analysis and differentiation of isobaric gemini surfactants, namely 16-7-16 and 18-3-18 (identical 
composition C43H92N22+, [M]2+ m/z 318). The differentiation of the isobaric gemini surfactants 
relied on the established characteristic chromatographic retention behaviour in combination with 
the analyte's unique mass spectrometric fingerprints (Table 2). Finally, the developed method 
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was not only applicable to the two classes of gemini surfactants, but it was also capable of 
separating the gemini surfactant Py-3-12, which contains two asymmetric tails, dodecyl chain 
and fluorescent pyrenyl-hexyl tail. The gemini surfactant Py-3-12 is generally used as a 
fluorescence probe for studying DNA complexation with gemini surfactants in addition to its 
gene transfection potential.[28,29] 
3.2 Method validation for bio-analysis of 16(Py)-S-2-S-(Py)16 and 16-3-16 
The method validation of the HILIC-LC-MS/MS method for the bio-analysis of two 
specific gemini surfactants, 16(Py)-S-2-S-(Py)16 and 16-3-16, was conducted in accordance with 
USFDA guidelines.[27] These two promising molecules are currently being evaluated at the pre-
clinical stage, assessing their toxicity alongside gene transfer capabilities. All method validation 
parameters are summarized in Table S2 (supplementary materials). 
3.3 Selectivity and matrix effects 
Selectivity was achieved as illustrated for both 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini 
surfactants per the MRM chromatograms in Figure S2 (supplementary materials). The absence of 
peaks in Figure S2A confirms that "double blank" samples contain no trace of either the analyte 
or the internal standard. Hence, the blank matrix has no interference or co-eluting peaks against 
the selective bio-determination of 16(Py)-S-2-S-(Py)16. Further, no cross-interference occurred 
between the analytes and internal standards. As an illustration, Figure S2B and Figure S2C for 
samples containing only the analyte 16(Py)-S-2-S-(Py)16 and internal standard 16(Py)-S-2-S-
(Py)16-d10, respectively, show peaks for only the respective compound. Thus as expected, no 
peaks of the analyte were detected in samples containing only the internal standard and vice 
versa. Similar data for 16-3-16 is shown in the supplementary materials (Figure S2D-F). 
The cellular matrix did not have an effect on the ionization efficiency, that is, neither 
ionization enhancement nor suppression was observed. The matrix effect was calculated to be 
approximately 101% for both 16(Py)-S-2-S-(Py)16 and 16-3-16 (criteria: >100% indicates 
enhancement, <100% indicates suppression). Determination of the matrix effect followed the 
method of Matuszewski et al,[30] as given below: Matrix effect(%) = Response post˗extraction spiked sampleResponse non˗extracted neat sample  × 100                                   (1); 
where the post-extraction spiked sample refers to standards spiked after extraction and contains 
the standard analyte added to extracted blank cell lysate. The non-extracted neat sample contains 
the analyte added to octanol (pure, cellular matrix-free). The determined value is the average for 
a set of 6 replicates. 
3.4 Calibration curve linearity and sensitivity 
During validation, the calibration curves for the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini 
surfactant analytes were linear at a concentration range of 50 – 5000 ng/mL, with an r2 value ≥ 
0.997 as shown in Figure S3 (supplementary materials). Figure 2 shows a representative 
chromatograms for 16(Py)-S-2-S-(Py)16 at 6, 50 and 5,000 ng/mL. The concentration 
determined as the lower limit of detection (LLOD) was based on a set limit of S/N ≥ 3; this led 
to an LLOD of 6 ng/mL for 16(Py)-S-2-S-(Py)16, (Figure 2C). The LLOD for 16-3-16 was 3 
ng/mL, with corresponding chromatograms given in the supplementary information (Figure S4). 
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HILIC-LC-MS/MS showed a substantially higher sensitivity in terms of ability to detect 
the target analytes in comparison with a recent cyano-based stationary phase LC-ESI-MS/MS 
method for the cellular analysis of 16-316 gemini surfactant, with reported LLOD of 180 
ng/mL.[15] With the reported cyano-LC-ESI-MS/MS method, triethylamine (TEA) along with 
gradient elution were needed and the analyte extraction from aqueous medium utilized n-octanol, 
which had a 71% recovery.[15] In the current work, the increased limit of detection up to 60-fold 
over previous work can be attributed to the change to the utilization of HILIC chromatography, 
coupled with the exclusion of the ion-pairing reagent, TEA, and better analyte recovery using the 
Bligh/Dyer lipid extraction method.[25] 
3.5 Recovery 
Liquid-liquid extraction of the 16(Py)-S-2-S-(Py)16 gemini surfactant analytes gave more 
than 96% recovery using the Bligh/Dyer lipid extraction method while the recovery was 67.5-
73.9% for octanol extraction (Table 3). The corresponding data for 16-3-16 is available in the 
supplementary materials (Table S3) showing similar trends. The recovery values were computed 
as proposed by Matuszewski et al,[30]: Recovery(%) = Response from extracted cellsResponse from spiked˗extracted cells  × 100                                   (2); 
where the response from extracted cells refers to standards spiked before extraction where 
samples were processed as per the extraction procedure. Response from spiked extracted cells 
refers to known standards spiked after the extraction procedure was employed on cells. 
For the separate extraction methods, the average recoveries were consistent for replicate 
determinations and were equal for the analyte (at three concentrations: lower, middle, and upper 
limit of quantitation). With such improved recovery (Figure 3 and Figure S5 in supplementary 
materials), our routine analyte extractions adopted the Bligh/Dyer extraction for its better 
efficiency, increasing the sensitivity of the LC-ESI-MS/MS method. 
3.6 Accuracy and precision 
In general, the validated method satisfied the USFDA-recommended accuracy and 
precision limits for all standard curve and quality control samples. Table 4 shows the accuracy 
and precision obtained for 16(Py)-S-2-S-(Py)16 gemini surfactant at four concentrations chosen 
per USFDA guidelines: LLOQ, LQC, MQC and HQC (corresponding data for 16-3-16 are 
available in the supplementary information, Table S4). For both the intra- and inter-day 
experiments, the accuracy (computed by expressing the observed concentrations as percentage of 
the theoretical values) varied between ~92 – ~110%. For precision, the values were within ~3 – 
~11% relative standard deviation for both intra- and inter-day cases. 
3.7 Stability 
Both the 16(Py)-S-2-S-(Py)16 and 16-3-16 analytes were stable beyond 24 h when stored 
at room temperature (bench top stability) and long-term stability when stored at -20 ˚C (Table 5, 
Table S5). The analytes also showed very good freeze/thaw stability after three freeze/thaw 
cycles. The autosampler stability was within USFDA guidelines for accuracy/precision and was 
determined for samples re-injected for analysis for up to two consecutive days. Overall, the 
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stabilities were within ~96 – ~105% accuracy and ~2 – ~9% precision for all the determinations 
(Table 5, Table S5). 
3.8 Bio-analysis of P/G/L-nanoparticle-treated cells 
Using the validated HILIC-LC-MS/MS methods, the uptake and intracellular deposition 
profile of the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants was studied within PAM 212 
cells treated with the gemini surfactant-containing P/G/L-nanoparticles. Figure 4 shows the 
results of an experiment as the intracellular concentration vs. time profile for 16(Py)-S-2-S-
(Py)16 and 16-3-16. The intracellular concentration of the analyte increased rapidly throughout 
the 5-h duration when the administered nanoparticles remain in contact with cells, followed by a 
noticeable decrease within the next 5 h after removal of the nanoparticle-dosed supernatant 
culture media. The intracellular amount showed a decreased by ~60% after the initial rise. A 
similar trend was observed in the case of 16-3-16; however, its intracellular decreawas ~40% of 
the maximum value and occurred less rapidly than that observed for 16(Py)-S-2-S-(Py)16. It is 
important to note that we ran many batches for the analysis of the cellular fate of gemini 
surfactants.  It was noted on occasions that during the post-validation application of the HILIC-
LC-MS/MS method, the LLOQ quality control sample within the standard curve did not pass in 
terms of accuracy, despite performing the full method validation according to the USFDA as 
discussed above. Therefore, for scientific accuracy, the cellular data in Figure 4 was only 
reported for data with concentration above 200 ng/ml which is the concertation of the second 
data point within the standard curve. This did not affect the results or the observed trend shown 
in Figure 4. 
The observations within the cellular data are consistent with a progressive nanoparticle 
uptake, which reached a maximum before a seeming depletion of the intracellular analyte. For 
both analytes, an observed intracellular remnant proportion did not undergo further depletion 
within the intracellular investigation lasting 54-h. For the 16-3-16 gemini surfactant, its partial 
depletion from the host cells is in disagreement with our recent reports[15,16] showing no 
depletion of this compound. The apparent discrepancy is attributed to differences in the 
extraction method and the extensive washing of treated cell cultures in the present work. 
Adequate washing steps were not conduced in the past work. Gemini surfactants tend to be 
adherent to bio-membranes and to plastics including walls of plastic cell culture containers. The 
washing was thus critical for eliminating potential gemini surfactants that is adherent to plastic 
walls or loosely adsorbed to exterior cell surfaces. To verify the results, the cell transfection 
experiments and the subsequent LC-ESI-MS/MS quantification procedures were repeated. The 
results reported attests to the consistency of the quantitative results on the uptake and subsequent 
intracellular profile of the investigated gemini surfactants. 
 
4. DISCUSSIONS 
The present study describes the development of  fast and simple HILIC-MRM-MS/MS 
methods that were applicable to 18 gemini surfactants with varying molecular structures (Table 
2). To-date, only one LC-ESI-MS/MS method has been reported for the quantification of gemini 
surfactants[15] but was only applicable to one class of gemini surfactants, the m-s-m family. 
This gives importance to the demonstrated applicability of the HILIC-LC-MS/MS platform to 
different structures of gemini surfactants. 
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The choice of HILIC chromatography (with sulfoalkyl betaine-based zwitterionic 
stationary phase, ZIC-HILIC column[31,32]) contributed to a high LLOD, which is 60-fold 
higher relative to the the method reported for the analysis of 16-3-16.[15] Our choice of the ZIC-
HILIC column, based on its compatibility with the diquaternary ammonium gemini surfactant 
analytes through +N/–SO3 HILIC mode interaction, led to more efficient chromatographic 
separation. Unlike the previous method,[15] no ion pairing reagent (i.e. TEA) was needed 
resulting in better ionization efficiency within the ESI source. TEA can compete for ionization 
within the ESI source resulting in undesirable ion suppression. Another major advantage of the 
HILIC-MS/MS is the use of isocratic elution rather than gradient system. In fact, the isocratic 
option was not possible when the cyano column was utilized.[15] 
The mobile phase was optimized to ensure that retention times are established to correlate 
with the gemini surfactant structural properties; a low buffer concentration (2.5 mM formate) 
was used. This buffer concentration (lower than concentrations of up to 50 mM in some cases) 
allows the chance for dominant interaction between the stationary phase and the analyte so that 
the gemini surfactants can display specific retention times as a result of their different structural 
features. Here, an added potential benefit is that low buffer concentrations are associated with 
better sensitivity as opposed to high buffer concentrations. In addition, the buffered mobile phase 
was optimized to pH 6.2; deviation from this pH resulted in weak and inconsistent response as 
well as unstable retention times. The HILIC system is very sensitive to variations in analytical 
conditions including pH and temperature. In fact, deviation from the optimized column 
temperature resulted in increased pressure within the column thus preventing chromatographic 
separation. 
In addition to adopting HILIC chromatography, a high efficiency analyte recovery was 
achieved through the use of Bligh/Dyer lipid extraction. Bligh/Dyer method uses 2:1 (v/v) 
methanol/chloroform binary extractant-solvent allowing for high compatibility with the gemini 
surfactants' amphiphilic nature[25] (as defined by having both hydrophobic and hydrophilic 
moieties, Figure 1). In fact, we have previously employed liquid-liquid extraction using either 
methanol or octanol with 63% and 70% recoveries[16], respectively.  While methanol may favor 
the solubilisation of the hydrophilic component within gemini surfactants, octanol is more 
compatible with the hydrophobic elements. The methanol/chloroform system of the Bligh/Dyer 
method can, therefore, solubilize both components within gemini surfactants resulting in 
approximately 98% extraction efficiency.  The high recovery is clearly illustrated in Figures 6 
and S6 in which a direct comparison with octanol extraction is shown. Overall, the superior 
sensitivity achieved for the reported HILIC-LC-MS/MS method underscores a strategic use of 
HILIC chromatography in conjunction with high analyte extraction efficiency and a suitable 
mobile phase. 
Data from the analysis of nanoparticle-treated cells showed an initial rise in the analyte 
intracellular concentration followed by a maximum and a somewhat more gradual decrease of 
the intracellular analyte. Herein, the findings are consistent with a progressive nanoparticle 
uptake, which reached a steady state before a seeming depletion of the intracellular analyte. Two 
events that may account for the intracellular depletion of the gemini surfactant are its bio-
transformation into metabolites and its exocytosis from the host cells. An advantage with LC-
ESI-MS/MS includes its versatility that allows adapting the described method, with major or 
minor modifications, for the investigation of both bio-transformation and exocytosis. The 
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knowledge regarding the bio-fate of gemini surfactants can impact decisions regarding the safe 
use of biomedical nanoparticles as well as provide insights into engineering new nanoparticles. 
CONCLUSION 
 We have developed simple and fast HILIC-LC-MS/MS methods for the determination of 
the 16(Py)-S-2-S-(Py)16 and 16-3-16 gemini surfactants in cells. The need for gradient elution as 
well as ion pairing reagent was eliminated, substantially simplifying the analytical methods. A 
high-efficiency liquid-liquid extraction was also adopted along with a ZIC-HILIC column to 
attain linear response and a run time of merely 4 minutes. The method is suitable for monitoring 
the fate of therapeutic nano-lipoplexes within cells. Obtained cellular data showed a pattern that 
grants additional investigations evaluating metabolite formation and assessing the subcellular 
distribution of tested compounds.   
We are currently investigating the intracellular deposition of gemini surfactants as well as 
metabolite formation. Such knowledge can shed light into the varying toxicities reported for 
gemini surfactants.[19,33] Finally, it should be noted that gemini surfactants have many other 
industrial applications[34] such as detergents, cosmetics, and solubilisation agents. The newly 
developed versatile HILIC-LC-MS/MS can serve as a starting point for the analysis of gemini 
surfactants regardless of the application. The developed method was applicable to various 
structures of gemini surfactants making it a universal method that can be adopted by others who 
wish to quantify gemini surfactants, regardless of the application. 
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FIGURE 1: Schematic representation of gemini surfactant general structure (A). The exact 
molecular structures of intact compounds and monitored product ions of 16-3-16: N,N-
bis(dimethylhexadecyl)-1,3-propanediammonium (B) and16(Py)-S-2-S-(Py)16: 1,1'-[ethane-1,2-
diylbis(sulfanediylhexadecane-1,2-diyl)]dipyridinium (C) 
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FIGURE 2: Chromatograms of the 16(Py)-S-2-S-(Py)16 gemini surfactant at LLOQ, ULOQ and LLOD. The 
relative response signal is shown for the analyte at: A) LLOQ – insert is a zoomed in spectrum of the analyte and B) 
ULOQ in relation to the internal standard, 16(Py)-S-2-S-(Py)16-d10, which was present at a constant concentration. 
C) Extracted ion chromatogram for 16(Py)-S-2-S-(Py)16 at LLOD. 
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Figure 3.  Analyte recovery efficiencies for Bligh/Dyer lipid extraction vs octanol extraction. Bligh/Dyer lipid 
extraction gave a better recovery (typically 98%) of the analyte and was the chosen liquid-liquid extraction 
method, departing from a recent report in which octanol extraction (70% efficiency) was used. 
Unsurprisingly, the new HILIC-LC-MS/MS methods reported herein show better sensitivity (60-fold 
increase). 
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Figure 4: 
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Figure 4.  Representative experiments showing the intracellular concentration vs. time profile of the 
gemini surfactants, 16(Py)-S-2-S-(Py)16 (top panel) and 16-3-16 (bottom panel). The 
intracellular concentration increased progressively throughout the duration of nanoparticle 
administration to cells, followed by a gradual decrease after removal of the nanoparticle-
dosed supernatant culture media. Each plotted data point represents mean ± SD, n = 3. 
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TABLES & TABLE CAPTIONS: 
Table 1. Conditions for MRM transitions of the analytes on AB Sciex 4000 QTRAP® System 
Analyte   Transition   DP* CE* CXE* 
Gemini surfactant Molecular Formula  [M]
2+ → [M − X]+ m/z  → m/z  (eV) (eV) (eV) 
16(Py)-S-2-S-(Py)16 C44H78N2S22+  [M]2+ → [M − C21H36N]+ m/z 349 → 396  30 22 10 
16(Py)-S-2-S-(Py)16 C44H78N2S22+  [M]2+ → [M − C34H59N2]+ m/z 349 → 203  30 22 10 
16(Py)-S-2-S-(Py)16-d10 C44H68D10N2S22+  [M]2+ → [M − C21H31D5N]+ m/z 354 → 401  30 25 10 
         
16-3-16 C39H84N22+  [M]2+ → [M − C16H33]+ m/z 290 → 355  40 21 10 
16-3-16 C39H84N22+  [M]2+ → [M − C33H70N2]+ m/z 290 → 86  40 35 6 
16-3-16-d66 C39H18D66N22+  [M]2+ → [M − C16D33]+ m/z 323 → 388  35 25 10 
*Abbreviation: 
  DP: declustering potential, CE: collision energy, CXE: collision cell exit potential; X: neutral loss 
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Table 2. HILIC-LC-MS/MS bio-analysis of 17 gemini surfactants with varying molecular structures 
         Gemini surfactant Spacer region   Tail region   MRM Retention 
Symbol 
 Name 
Molecular 
formula  Name 
Molecular 
formula  
transitions 
m/z  → m/z 
time 
(min) 
12-3-12 Propyl C3H6  Dodecyl C12H25  234 → 299 2.96 
12-4-12 Butyl C4H8  Dodecyl C12H25  241 → 313 2.91 
12-8-12 Octyl C8H16  Dodecyl C12H25  269 → 369 2.57 
12-12-12 Dodecyl C12H24  Dodecyl C12H25  297 → 425 2.43 
12-16-12 Hexadecyl C16H32  Dodecyl C12H25  325 → 481 2.42 
16-3-16 Propyl C3H6  Hexadecyl C16H33  290 → 355 2.86 
16-7-16 Heptyl C7H14  Hexadecyl C16H33  318 → 411 2.52 
18-3-18 Propyl C3H6  Octadecyl C18H37  318 → 383 2.44 
18-7-18 Heptyl C7H14  Octadecyl C18H37  346 → 439 2.37 
18:1-3-18:1 Propyl C3H6  Octadec-9-ene C18H35  316 → 381 2.57 
18:1-6-18:1 Hexyl C6H12  Octadec-9-ene C18H35  337 → 423 2.50 
12(Py)-S-2-S-(Py)12 1,2-ethanedithiol C2H4S2  Dodecyl C12H25  293 → 340 2.86 
14(Py)-S-2-S-(Py)14 1,2-ethanedithiol C2H4S2  Tetradecyl C14H29  321 → 368 2.79 
16(Py)-S-2-S-(Py)16 1,2-ethanedithiol C2H4S2  Hexadecyl C16H33  349 → 396 2.78 
18(Py)-S-2-S-(Py)18 1,2-ethanedithiol C2H4S2  Octadecyl C18H37  377 → 424 2.63 
12-7NH-12 Dipropylamine C6H13N  Dodecyl C12H25  263 → 356 7.12 
Py-3-12 Propyl C3H6  
Dodecyl, 
Hexapyrenyl, 
C12H25, 
C22H23 
 293 → 417 2.96 
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Table 3. Recovery of 16(Py)-S-2-S-(Py)16 from the aqueous cellular matrix 
   Bligh/Dyer extraction    Octanol extraction  
Theoretical 
concentration 
 Extracted cells 
(mean ± SD, ng/mL) 
Spiked extracted 
cells  
 (mean ± SD, ng/mL) 
Recovery 
(%) 
 Extracted cells  
(mean ± SD, ng/mL) 
Spiked extracted 
cells  
(mean ± SD, ng/mL) 
Recovery 
(%) 
16(Py)-S-2-S-(Py)16         
50 ng/mL (LLOQ)  47.44 ± 4.73 48.31 ± 3.74 96.2  32.88 ± 4.42 48.73 ± 4.74 67.5 
150 ng/mL (LQC)  151.16 ± 10.61 155.36 ± 9.31 97.3  104.51 ± 11.02 145.36 ± 8.98 71.9 
375 ng/mL (MQC)  369.75 ± 41.33 377.68 ± 37.93 97.9  270.87 ± 19.16 375.68 ± 47.92 72.1 
4375 ng/mL (HQC)  4309.51 ± 359.41 4344.25 ± 222.53  99.2   3209.64 ± 179.11 4343.22 ± 182.33  73.9  
 
…
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Table 4. Intra- and inter-day accuracy and precision in the analysis of 16(Py)-S-2-S-(Py)16 
Quality Control  Observed concentration 
(mean ± SD, ng/mL) 
Accuracy 
(%) 
Precision 
(%RSD) 
INTRA-DAY:    
 Analysis Day (#)    
LLOQ: 50 ng/mL Day 1 46.44 ± 4.73 92.9 10.2 
 Day 2 51.26 ± 5.08 102.5 9.9 
 Day 3 55.06 ± 3.33 110.1 6.0 
LQC: 150 ng/mL Day 1 145.96 ± 8.61 97.3 9.0 
 Day 2 154.64 ± 13.9 103.1 8.4 
 Day 3 161.14 ± 9.99 107.4 6.2 
MQC: 375 ng/mL Day 1 363.75 ± 11.33 97.0 3.1 
 Day 2 393.36 ± 21.73 104.9 5.5 
 Day 3 369.03 ± 19.77 98.4 5.4 
HQC: 4375 ng/mL Day 1 4032.50 ± 359.41 92.2 8.9 
 Day 2 4411.38 ± 272.55 100.8 6.2 
 Day 3 4321.99 ± 323.09 98.8 7.5 
INTER-DAY:    
 Concentration    
LLQC 50  ng/mL 51.15 ± 4.84 102.3 9.7 
LQC 150 ng/mL 157.25 ± 10.84 104.8 7.7 
MQC 375 ng/mL 375.38 ± 17.61 100.1 4.7 
HQC 4375 ng/mL 4255.29 ± 318.53 97.3 7.5 
…
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Table 5. Stability of 16(Py)-S-2-S-(Py)16 analyte within the sample matrix 
Quality Control Storage condition/ period 
Observed concentrations 
(mean ± SD, ng/mL) 
Accuracy 
(%) 
Precision 
(%RSD) 
     
LQC: 150 ng/mL 0 h 150.33 ± 11.14 102.3 9.7 
 24 h on bench top 148.83 ± 10.04 99.3 7.7 
 Three freeze/thaw cycles 145.87 ± 13.13 94.3 8.5 
 ‒20 ˚C for 105 days (LT) 146.16 ± 9.91 96.7 10.1 
 48 h extract in autosampler  150.15 ± 8.43 96.6 9.2 
     
MQC: 375 ng/mL 0 h 365.03 ± 18.18 102.3 9.7 
 24 h on bench top 381.73 ± 17.98 99.3 7.7 
 Three freeze/thaw cycles 355.05 ± 18.17 94.3 8.5 
 ‒20 ˚C for 105 days (LT) 355.22 ± 18.68 96.7 10.1 
 48 h extract in autosampler  375.88 ± 15.76 96.6 9.2 
     
HQC: 4375 ng/mL 0 h 4358.23 ± 198.08 102.3 9.7 
 24 h on bench top 4398.23 ± 201.27 99.3 7.7 
 Three freeze/thaw cycles 4151.53 ± 229.38 94.3 8.5 
 ‒20 ˚C for 105 days (LT) 4324.56 ± 186.83 96.7 10.1 
 48 h extract in autosampler  4308.93 ± 191.77 96.6 9.2 
LT (long term): ‒20 ˚C for 105 days 
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